Correction to: Optimising the Benefits of SGLT2 Inhibitors for Type 1 Diabetes

類似資料

• Optimising the Benefits of SGLT2 Inhibitors for Type 1 Diabetes
  著者:: Evans, Marc, 等
  出版事項: (2019)
• Correction to: SGLT2 Inhibitors: Cardiovascular Benefits Beyond HbA1c—Translating Evidence into Practice
  著者:: Ali, Amar, 等
  出版事項: (2019)
• SGLT2 Inhibitors: Cardiovascular Benefits Beyond HbA1c—Translating Evidence into Practice
  著者:: Ali, Amar, 等
  出版事項: (2019)
• SGLT2 Inhibitors: Slowing of Chronic Kidney Disease Progression in Type 2 Diabetes
  著者:: Wheeler, David C., 等
  出版事項: (2020)
• SGLT2 Inhibitors in Type 2 Diabetes Management: Key Evidence and Implications for Clinical Practice
  著者:: Wilding, John, 等
  出版事項: (2018)